According to our latest research, the global Novel Coronavirus (COVID-19) Vaccine market size will reach USD million in 2028, growing at a CAGR of % over the analysis period.
Global Novel Coronavirus (COVID-19) Vaccine Scope and Market Size
This report focuses on the global Novel Coronavirus (COVID-19) Vaccine status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Novel Coronavirus (COVID-19) Vaccine development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America, etc.
Segment by Type
DNA
RNA
Others
Segment by Application
Mild Symptom Patient
Critically Ill Patient
By Region
North America
Europe
China
Japan
Southeast Asia
India
Central & South America
By Company
Inovio Pharmaceuticals
Takis Biotech (Evvivax)
Zydus Cadila
Codagenix, Inc.
GeoVax, Inc.
Bravovax
Janssen Pharmaceutical Companies
Altimmune
Vaxart
CanSino Biologics
ExpreS2ion Biotechnologies ApS
Clover Biopharmaceuticals
GSK
Vaxil Bio Ltd.
Generex
Novavax, Inc.
Sanofi Pasteur
Baylor
iBio, Inc.
Moderna, Inc.
Curevac
ImmunoPrecise